THE ROLE OF MATRIX METALLOPROTEINASE-9 AND ITS TISSUE INHIBITORY-1 AS A POSSIBLE PREDICTOR OF CEREBROVASCULAR PATHOLOGY
Keywords:
matrix metalloproteinase (MMP-9), tissue inhibitor of matrix metalloproteinase (TIMP-1), cerebrovascular diseasesAbstract
87 patients with cerebrovascular diseases and strokes aged 50 to 78 years were examined, the average age was 67.9 ± 4.8 years. In patients with cerebrovascular diseases, a tendency was revealed to increase the level of MMP-9, TIMP-1 and their ratio in the blood serum, the indicators of which can be regarded as a predictor of the severity of the cerebrovascular process.
References
Berezhanskaya S.B., Lukyanova E.A., Zhavoronkova T.E., Kaushanskaya E.Y., Sozaeva D.I. Modern concept of structural and functional organization of the blood-brain barrier and the main mechanisms of its resistance violation resistance. Pediatrics. 2017;96(1):135-141. (in Russ).
Grigorkevich O.S., Mokrov G.V., Kosova L.Y. Matrix metalloproteinases and their inhibitors // Pharmacokinetics and Pharmacodynamics. 2019; 2: 3-16. DOI: 10.24411/2587-7836-2019-10040. (in Russ).
Konstantinova E.V., Shurdumova M.H. Destruction and remodeling of extracellular matrix in the pathogenesis of acute focal cerebral ischemia pathogenesis of acute focal cerebral ischemia. Consilium Medicum. 2015; 17 (12): 50-54. (in Russ).
Markelova E.V., Zdor V.V., Romanchuk A.L., et al. Matrix metalloproteinases: their interrelation with cytokine system, diagnostic and prognostic potential // Immunology, Allergology, Infectology. - 2016;2:11-22. (in Russ).
Paltsin A.A. Matrix proteinases in stroke / Pathologic physiology and experimental therapy experimental therapy. 2017;61(3):110-115. (in Russ).
Reznik E.V., Krupnova E.S., Bilinskaya M.A., Yasnovskaya A.A., Nikitin I.G., Perekhodovi S.N. Matrix metalloproteinases, their inhibitors and inflammatory markers in patients with chronic heart failure patients with chronic heart failure. RMZ. 2023;9:12-17. (in Russ).
Teplyakov A.T., Andriyanova A.V., Pushnikova E.Yu. et al. Tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) as an independent marker of myocardial ischemic remodeling in chronic insufficiency. Siberian Medical Journal. 2014;29(2):28-34. (in Russ).
Shadrina AS, Plieva YZ, Kushlinsky DN, Morozov AA, Filipenko ML, Chang VL, Kushlinsky NE Classification, regulation of activity, genetic polymorphism of matrix metalloproteinases in norm and pathology / Almanac of Clinical Medicine. 2017;45(4):266–279. doi: 10.18786/2072-0505-2017-45-4-266-279. (in Russ).
Translated with DeepL.com (free version) Freitas-Rodríguez S, Folgueras AR, López Otín C. The role of matrix metalloproteinases in aging: Tissue remodeling and beyond. Biochim Biophys Acta, 2017; 0167-4889(17)30118-0. doi: 10.1016/j.bbamcr.2017.05.007.
Laronha, H. Structure and Function of Human Matrix Metalloproteinases / H. Laronha, J. Caldeira // Cells. 2020; 9(5):1076.
Levin M, Udi Y, Solomonov I, Sagi I. Next Generation Matrix Metalloproteinase Inhibitors – Novel Strategies Bring New Prospects. Biochim Biophys Acta, 2017;0167-4889(17)30161-1. doi: 10.1016/j.bbamcr.2017.06.009.
Van Lint, P. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation / P. Van Lint, C. Libert // J Leukoc Biol, 2007;82(6):1375-1381.
